Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 27.00M | $41.0M | 7.96% | +19.70M | 2026-06-30 |
| State Street Corp | 21.47M | $32.0M | 6.33% | +11.80M | 2026-06-30 |
| Vanguard Capital Management LLC | 14.37M | $21.0M | 4.24% | +568.5K | 2026-06-30 |
| Millennium Management LLC | 14.37M | $21.0M | 4.24% | +436.1K | 2026-06-30 |
| Geode Capital Management, LLC | 8.87M | $13.0M | 2.62% | +4.64M | 2026-06-30 |
| Rtw Investments, LP | 6.67M | $10.0M | 1.97% | -- | 2026-06-30 |
| UBS Group AG | 5.18M | $7.0M | 1.53% | -2.10M | 2026-06-30 |
| Ikarian Capital, LLC | 3.96M | $6.0M | 1.17% | -- | 2026-06-30 |
| GMT Capital Corp | 3.51M | $5.0M | 1.03% | -- | 2026-06-30 |
| Marshall Wace, LLP | 3.41M | $5.0M | 1.01% | -4.64M | 2026-06-30 |
